Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Linked To More Coronavirus Cases In Boston

International Meeting At Center Of Outbreak

Executive Summary

Company has instructed employees and contractors to self isolate to prevent further spread of COVID-19.

You may also be interested in...



How COVID-19 Defined 2020 For Biopharma

Development of vaccines usually takes years, but drug makers whittled the process down to a matter of months amid a concerted response to a global health threat.

From Early 2020 To Q3: Biogen Shifts Aducanumab Filing Expectations Again

The company remains confident in US FDA approval for the first disease-modifying Alzheimer’s drug based on current data, but Biogen needs more time to complete the BLA filing.

In A Volatile Time, Pharma Reassures Business Remains Steady

Amid a stock market freefall spurred largely by coronavirus uncertainty, big pharma sought to reassure investors and the public that supply disruptions are not an immediate concern and they are monitoring business operations day-by-day.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel